Kim De Veirman
Brussels, BRU 1090, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications
Molecular basis for targeting Caveolin-1 in multiple myeloma therapy.
Journal: Expert opinion on therapeutic targets
Published: January 26, 2026
IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 18, 2025
T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.
Journal: Signal transduction and targeted therapy
Published: November 03, 2025
A fast-progressing orthotopic ovarian cancer model reveals synergistic antitumor effects of AXL-targeting nanobodies and Olaparib.
Journal: Gynecologic oncology reports
Published: September 04, 2025
Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma.
Journal: Journal of extracellular vesicles
Published: July 08, 2025
Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.
Journal: Experimental hematology & oncology
Published: July 04, 2025
The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism.
Journal: Cancer letters
Published: June 20, 2025
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.
Journal: Journal of hematology & oncology
Published: June 03, 2025
Neural control of Immunotherapy: how Tumor-innervation shapes Anti-Tumor immune responses.
Journal: Brain, behavior, and immunity
Published: May 20, 2025
Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.
Journal: Journal for immunotherapy of cancer
Published: April 05, 2025
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism.
Journal: Molecular oncology
Published: February 24, 2025
Last Updated: 09/26/2026